The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
Tired of dancing to the tunes of international funders, and doubtful that long-promised national grants will come, a handful of African biomedical scientists have turned to private investors to bankroll their dreams of autonomy in the lab.
The decision, which concerns the removal of a sugar molecule on the surface of cells in a line of domestic pigs, marks the first time an approval has been granted for both purposes simultaneously.
Super-resolution imaging identifies abnormalities in the hair-like protrusions on a cell’s surface and may help facilitate earlier detection of primary ciliary dyskinesia.
Three-dimensional polymer matrices offer researchers a new representation of the extracellular matrix that can be used to study the growth of cancer cells.
All six calves inherited the gene for preventing horn growth, but four also got a piece of the plasmid used to introduce the sequence to their dad—complicating regulatory approval.
Unlike biotech tools adapted from nature, the invention was entirely conceived by humans and represents one of the few proteins made from scratch in the lab.
At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.